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Abstract
Background: In previous work, we reported the development of caCORRECT, a novel microarray quality control
system built to identify and correct spatial artifacts commonly found on Affymetrix arrays. We have made recent
improvements to caCORRECT, including the development of a model-based data-replacement strategy and
integration with typical microarray workflows via caCORRECT’s web portal and caBIG grid services. In this report, we
demonstrate that caCORRECT improves the reproducibility and reliability of experimental results across several
common Affymetrix microarray platforms. caCORRECT represents an advance over state-of-art quality control
methods such as Harshlighting, and acts to improve gene expression calculation techniques such as PLIER, RMA
and MAS5.0, because it incorporates spatial information into outlier detection as well as outlier information into
probe normalization. The ability of caCORRECT to recover accurate gene expressions from low quality probe
intensity data is assessed using a combination of real and synthetic artifacts with PCR follow-up confirmation and
the affycomp spike in data. The caCORRECT tool can be accessed at the website: http://cacorrect.bme.gatech.edu.
Results: We demonstrate that (1) caCORRECT’s artifact-aware normalization avoids the undesirable global data
warping that happens when any damaged chips are processed without caCORRECT; (2) When used upstream of
RMA, PLIER, or MAS5.0, the data imputation of caCORRECT generally improves the accuracy of microarray gene
expression in the presence of artifacts more than using Harshlighting or not using any quality control; (3)
Biomarkers selected from artifactual microarray data which have undergone the quality control procedures of
caCORRECT are more likely to be reliable, as shown by both spike in and PCR validation experiments. Finally, we
present a case study of the use of caCORRECT to reliably identify biomarkers for renal cell carcinoma, yielding two
diagnostic biomarkers with potential clinical utility, PRKAB1 and NNMT.
Conclusions: caCORRECT is shown to improve the accuracy of gene expression, and the reproducibility of
experimental results in clinical application. This study suggests that caCORRECT will be useful to clean up possible
artifacts in new as well as archived microarray data.
Background
The reproducibility and reliability of microarray data is a
major issue that must be addressed before microarrays
can reach their full potential as a clinical molecular pro-
filing tool for personalized and predictive medicine [1].
The FDA has completed phase-I of the MicroArray
Quality Control (MAQC) project, which demonstrated
general reproducibility among different array platforms
and PCR, but came just short of offering concrete gui-
dance on which processing methods to use when ana-
lyzing microarray data [2]. Recently published results
from MAQC-phase II efforts demonstrate that well-
designed microarray-based classification is reliable
across experiments, and that in some cases, microarray-
based classification can outperform existing clinical pre-
dictors [3,4]. The current status of microarray quality
control (QC), however, is still a relatively anecdotal and
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methods. Tools such as dChip [5,6], MAS5.0 [7],
RMAExpress [8-10], and PLIER [11] have been devel-
oped to improve the accuracy of microarray gene
expression data by taking advantage of Affymetrix’s
high-density array design. These model-based tools use
perfect match (PM) and mismatch (MM) information as
well as the redundancy inherent in a probe set to gener-
ate estimates of gene expression, which are generally
robust to failures of one or a few probes. While these
tools use sensible methods of background correction,
normalization, and statistical outlier detection, they fall
short in two important areas. First, they do not incorpo-
rate adequate spatial information into the outlier detec-
tion methods and second, they do not incorporate
outlier information into their normalization routines.
caCORRECT [12] addresses these deficiencies and seeks
to replace or augment existing methods to improve the
reproducibility of microarray experimentation.
Quality Assurance (QA) tools, such as SmudgeMiner
[13] and arrayMagic [14] provide intuitive images of
damaged arrays through the use of heat maps, but they
do not provide correction methods for observed errors.
In fact, RMA and dChip also readily provide similar
visualizations of chip errors, but they do not use that
visualized information during probe outlier detection.
Harshlighting [15,16] is similar to caCORRECT in that
it identifies an assortment of compact and widely scat-
tered artifacts, by leveraging techniques from the field of
image processing, such as sliding windows and back-
ground assessment. Harshlighting, however, defines a
chip’s “error image” as a simple residual (i.e. subtrac-
tion) from the median. Harshlighting therefore ignores
the differing natural variance of probes and neglects to
account for global chip-to-chip variation, which is
usually correctable with a simple normalization step.
The R implementation of Harshlighting does allow for
the input of user-generated error images, but this proce-
dure is relatively skill-intensive. As a known issue, the
authors of Harshlighting point out the appearance of
“ghosting” artifacts i.e. the false appearance of artifacts
on clean chips as a result of comparison to a true arti-
fact on another chip in the batch. Whereas Harshlight-
ing attempts to correct for this phenomenon by using a
median in its error heat map calculation (as opposed to
the more outlier-sensitive measure, the arithmetic
mean), caCORRECT avoids the ghosting problem by
iteratively identifying artifacts and directly omitting
them from calculations altogether.
The LPE and CPP adjustments [17] have also been
suggested as a way to correct spatial flaws on microar-
rays. Artifact probes are identified by LPE and CPP
similarly to caCORRECT, i.e. their d∗
klr measure is analo-
gous to caCORRECT’s zj and both methods use
n e i g h b o r i n gi n f o r m a t i o n .c a C O R R E C T ,h o w e v e r ,a l l o w s
for iterative calculation of this score, and thus allows for
the same probe location to be corrected on more than
one chip in a batch, whereas the methods of Arteaga-
Salas et al. do not [12].
Previously, we have shown that using caCORRECT as
a preprocessing step increases the reproducibility of bio-
marker selection as measured by similarity of ranked
gene lists during independent cross-validation from
large microarray datasets [12]. We have also shown that
the spatial locations of proposed biomarkers (differen-
tially expressed genes) in published microarray studies
often are correlated or anti-correlated with the location
of chip artifacts identified using caCORRECT [18].
Finally, we have constructed caBIG grid services for
much of the functionality of caCORRECT [19]. Since
these initial publications, improvements have been made
to the caCORRECT algorithms, which have allowed
more conclusive validations. Specifically, we have imple-
mented a new bad-data-replacement algorithm (pre-
viously only median replacement was possible), and we
have made user-centered design changes to allow more
seamless integration with existing gene expression calcu-
lation protocols. caCORRECT’s website currently offers
gene expression output from RMA, PLIER, and MAS5.0.
For users who wish to use other methods, such as the
popular tool dChip, they can run the tools directly,
using the clean cel file output option provided by
caCORRECT. These validation results, which include
the discovery of two biomarkers for renal cell carcinoma
subtyping, as well as the description of improved meth-
ods are the subject of this manuscript.
Results
Artifact removal and replacement
Many artifacts were easily visible using the heat map
function provided by caCORRECT, and one such exam-
ple of mixed artifacts observed in published data is
shown in Figure 1. The input and output of caCOR-
RECT’s artifact identification procedure are visualized,
demonstrating the process by which continuous scoring
of the quality of individual probes (dark color indicating
poor quality in panel A) is combined to determine the
binary classification of “artifact or not” (artifacts shown
in bright red in panel B). Note that not every probe
with a poor score was flagged as an artifact, as local
areas of high variance are expected as a result of actual
variance in gene expression among samples. For com-
parison, the artifact labels provided by Harshlighting are
shown for both diffuse and compact artifacts in panel C
and D respectively, with black and white indicating arti-
facts. This example supports the general trend that
caCORRECT’s automated artifact identification is con-
servative. It is our experience that human observers
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able than caCORRECT does. Harshlighting on the other
hand, tends to be more aggressive in flagging regions of
chips as artifactual. We chose conservative artifact iden-
tification over a more aggressive scheme because
caCORRECT was designed to identify spatial artifacts
upstream of the more specific model-based outlier
detection employed by most probe summarization
methods, such as RMA, PLIER, and MAS5.0. Generally
speaking, probe summarization is the fitting of a regres-
sion model to the probe intensity data from a chip or
set of chips. While individual methods differ on how the
model is set up (notably how they handle information
from mismatch probes), they are the same in that the
model-fitting procedures allow for different weights or
affinities for each probe’s contribution to gene expres-
sion. During this model-fitting process, single outlier
probes are easily detected and ignored because they do
not fit the model well. caCORRECT is not designed to
detect or remove such isolated, single probe defects,
because RMA, MAS5.0 and PLIER are already very good
at this task. With large artifacts that affect many probes,
however, model-based outlier removal becomes much
more difficult. To help users interpret the success or
failure of the probe summarization (i.e. model-fitting)
process, client software such as RMAExpress, and now
caCORRECT, visualizes the residuals (difference, or
error) of every probe intensity from the model collec-
tively as a heat map. Close interpretation of these resi-
duals reveals how well a particular model fits the data.
Figure 2 represents a case study using residual images
to compare how caCORRECT and RMA react to the
presence of a scratch on an Affymetrix Hu-6800 chip
from the West dataset. We chose a data set based on
this older array platform, because, on the Hu-6800 chip,
all probes which contribute to a single gene expression
value are actually arranged in contiguous regions on the
microarray (as opposed to newer chip layouts which dis-
tribute related probes randomly). This property allows
for easier visual interpretation of residual images. Panel
A of Figure 2 shows the residuals produced by the
caCORRECT regressive gene expression model before
any attempt to identify artifacts. The blue (negative
Figure 1 Sample heat map and artifact segmentation result.
Panel A shows a heat map of the first variance score generated by
caCORRECT for one chip in the West et al. dataset, with dark color
indicating poor quality. Panel B shows the variance scores after
artifacts have been flagged, with red indicating artifacts, and the
rest of the probes colored by their final variance score as in panel
A. Panel C and panel D show the compact and diffuse artifacts
detected by Harshlighting in black and white with clean data in
grey.
Figure 2 Effect of scratch artifact and removal on residual
images. All 4 panels are heat maps with high positive values
colored in red, values near zero in white, and large negative values
colored in blue. The panels were not all generated identically, (i.e.
panel C by RMAExpress, and others by caCORRECT), and so the
scales and ranges may differ without loss of central meaning. All
images show residuals between observed intensity and that
expected by the underlying model. Thus, red color indicates higher
than expected intensity, blue color indicates lower than expected
intensity and white indicates good fit to the model. Panel A shows
(caCORRECT) residuals from the original chip, panel B shows the
(caCORRECT) residual after artifact flagging by caCORRECT, panel C
shows the (RMA) residual produced by RMAExpress from the
original chip, and panel D shows the (caCORRECT) residual
produced after median-replacement form Harshlighting. Systematic
blue color surrounding the red scratch (prominent in A and weaker
in C) reveals poor model fit to the data, which is likely to cause an
overestimate of gene expression for these probes. The figure
suggests that caCORRECT has identified this scratch better than
RMA has, and modeled the data better than Harshlighting has,
resulting in a more accurate gene expression than either. The
effective reduced image resolution for the RMA panel is due to the
way that RMA handles pairs of perfect match (PM) and mismatch
(MM) probes together when calculating residuals, whereas
caCORRECT processes PM and MM probes independently of one
another. Portions of this figure are reproduced with permission from
[23].
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(positive residual) demonstrate the ambiguity that arises
when more than one outlier is present in a probe set.
Without prior knowledge, the regressive model cannot
determine whether the artifact data are too high, or the
non-artifact data are too low. caCORRECT, however,
identifies the actual scratched region as artifact, and the
surrounding data as non-artifact. With this knowledge,
the regressive model fits only to the non-artifact data.
The resulting residuals that are calculated after caCOR-
RECT are shown in panel B of Figure 2. The white
region surrounding the scratch (and redness of the
scratch itself) is evidence that caCORRECT has success-
fully disambiguated the decision. The data within the
scratch are to be ignored, and the resulting model
should use only the surrounding probe data to estimate
gene expression. Panel C of Figure 2 shows residuals to
the model produced by RMAExpress alone. RMA
includes its own outlier detection, but RMA’sd e t e c t i o n
is not informed by spatial location, and thus cannot
recognize a scratch as such. The output from RMA sug-
gests that RMA does a fair job of disambiguating the
scratch from the surrounding data, but some areas of
blue still exist near the scratch, suggesting that the gene
expression values for these probe sets have been overes-
timated. Finally, the residual image produced after the
median data replacement of Harshlighting, shown in
panel D, suggests that most if not all of some probe set
calculations are based solely on the median-replaced
data, with non-artifact data in surrounding regions
being regarded as outlier data. These problems have
been almost completely avoided by caCORRECT,
however.
Effect of artifact aware quantile normalization on
synthetic artifact data
Figure 3 illustrates the difference between standard
quantile normalization and artifact-aware normalization.
In this experiment the Schuetz et al. dataset has been
modified with two large artifacts on one chip for illus-
trative purposes. As can be seen in the raw intensities
(top panel), the synthetic artifacts (leftmost and right-
most modes in the red curve) cause a differently shaped
distribution than that of a high quality chip (blue curve).
Once standard quantile normalization is performed, a
‘warping’ of the high quality chip can be seen in the way
that each of the distributions is now identically and
incorrectly trimodal (middle panel). After caCORRECT
artifact-aware normalization has been performed, the
high quality chip returns to its natural distribution (bot-
tom panel, blue curve). The chip with the artifacts still
has two clear modes for its artifacts, but now the
remaining non-artifactual data on the chip with the arti-
facts (central mode, red curve) has been properly
Figure 3 Effect of quantile normalization or caCORRECT
artifact-aware normalization on probe intensity distribution.
The top panel shows the distribution of probe intensities of two
microarray chips, one of which has been affected by both a high
intensity and a low intensity artifact (red), and the other which is of
good quality (blue). The middle panel shows the distribution of
these chips after quantile normalization. The bottom panel shows
the distributions of these chips after caCORRECT artifact-aware
quantile normalization.
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ity chip (blue curve).
Effect of applied artifacts and preprocessing on gene
expression
We monitored the effect of applied quality insults on
gene expression using the two popular probe summari-
zation methods of RMA and MAS5.0. Figure 4 demon-
strates the correspondence of gene expression, before
and after introduction of artifacts by an independent
third party. Two phenomena are readily observable:
First, for the “black hole” artifacts which lower probe
intensities on the microarray, the MAS5.0 algorithm has
the tendency to call many of the genes ‘absent’,a n d
report the gene expression abnormally low (Figure 4
panel C). caCORRECT is able to almost completely
reverse this trend, and is able to help MAS5.0 produce
appropriate gene expression values for most of these
probe sets.
Second, for the “hot spot” artifacts that raise probe
intensities on the microarray, the RMA algorithm has
the tendency to underestimate gene expression and lose
Figure 4 Scatter plots of gene expression after quality insult versus original gene expression. Data shown are for one representative chip,
and all probe sets on the HG-U133A platform. Gene Expression is calculated either independently with MAS5.0 or with RMA as part of a batch
containing the 81 independent chips in the original Hess et al. training set. caCORRECT normalization is performed independently for each chip
as part of a batch with the 81 chips of the Hess et al. training set. Units of gene expression are on the scale of the natural log of probe
intensity. caCORRECT improves gene estimation in all cases, as exhibited by scatter plots closer to a line with unitary slope. This figure has been
reproduced with permission from [23].
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sample (Figure 4 panel B, red). This is presumably a
result of the warping issues related to quantile normali-
zation discussed in the previous section. This phenom-
enon also happens to low-expressing genes in RMA to a
lesser extent for the black hole artifacts (Figure 4 panel
D, red). Chips processed first with caCORRECT and
then with RMA do not exhibit either of these warping
behaviors (Figure 4, blue).
We then created our own synthetic insults in order to
compare caCORRECT with Harshlighting for the ability
to moderate effects of single artifacts on gene expres-
sion, as measured by the probe summarization methods
RMA, PLIER, and MAS5.0. As a control to these com-
mon methods, which include normalization and outlier
detection inherently, we also measured expression with
our simple xb,p,j = θp,jab,p + εb,p,j regression method
“TAXY” detailed in the methods section, which does
not contain special considerations for outlier data.
Three conditions were tested for each method of gene
expression measurement: (1) using original data that
was not preprocessed; (2) using data that was processed
with caCORRECT; and (3) using data that was pro-
cessed with Harshlighting. We calculated the error
caused by a given artifact as the average absolute differ-
ence, in the log domain, between the original gene
expression and the expression measured after introduc-
tion of artifact. This measure is similar in concept to
average relative error in gene expression in the linear
domain.
Figure 5 shows the effect of artifact magnitude on
gene expression. When the magnitude of the applied
artifact was increased, the magnitude of error then
increased for data that was not preprocessed, as well as
for data processed with Harshlighting. In contrast, the
magnitude of observed error remained constant, or even
decreased, for data processed with caCORRECT. We
expect that this is due to the phenomenon that as arti-
facts become more severe, they also become more
obvious to caCORRECT. Even though harsher artifacts
introduced more overall noise to the system, caCOR-
RECT became better at identifying and removing them.
For RMA, caCORRECT outperformed both Harsh-
lighting and unprocessed data for artifacts stronger than
1.5 fold. For PLIER and MAS5, however, caCORRECT
outperformed unprocessed data only for intensity redu-
cing artifacts. This suggests that caCORRECT is not sui-
table for helping MAS5.0 or PLIER to identify subtle
artifacts, but that in the case of such subtle artifacts,
caCORRECT does not reduce performance.
Figure 6 shows the effect of artifact size on gene
expression. With the magnitude of artifact fixed, an
increasing artifact size increased error for each gene
expression and preprocessing method tested. For RMA,
caCORRECT outperformed both Harshlighting and
unprocessed data for artifacts larger than 25 probes
across. For PLIER and MAS5, however, caCORRECT
outperformed unprocessed data only for intensity-redu-
cing artifacts. Overall, results suggest that the size, mag-
nitude, and sign of an artifact all affect the final error in
gene expression differently, depending critically on the
gene expression method being used.
Identification of differentially expressed genes
Having established that caCORRECT could improve the
accuracy of gene expression derived from microarrays in
the presence of spatial artifacts, we set out to determine
if this improved accuracy of gene expression would
translate to improved efficiency in identifying candidate
genes to serve as biomarkers for disease. Briefly, we first
identified differentially expressed genes between sub-
types of renal cell carcinoma from the Schuetz et al.
microarray data, then we performed a small PCR pilot
study to verify these findings, and finally we tested a
much larger cohort of genes and samples via a PCR
core facility. While results could not be directly quanti-
tatively compared between experiments, trends in gene
expression, such as ratios among biomarkers were gen-
erally preserved. Figure 7 shows the trends in gene
expression for the two most reliable biomarkers identi-
fied during this process: NNMT and PRKAB1.
During the first PCR pilot study, we found only anec-
dotal evidence suggesting that using caCORRECT on
real data could improve the reliability of biomarker
selection. We believed that this could probably be attrib-
uted to the relatively high quality of the original chips in
the Schuetz et al. study, and thus decided to artificially
reduce the quality of the data in order to amplify any
affect that caCORRECT may have. Figure 8 shows
examples of our synthetic artifacts (Panels C and D)
applied to the Schuetz et al. dataset as well as the unal-
t e r e dv e r s i o n so ft h o s ec h i p s( P a n e lAa n dB )a sv i s u a -
lized by the post-caCORRECT residual images. While
the synthetic artifacts may appear more visually stun-
ning than the artifacts “naturally” found in this dataset,
they are comparable with those found on other microar-
rays, such as the one shown covering the left hand side
of the chip in Figure 1.
Figure 9 shows Receiver Operating Characteristic
(ROC) curve analysis of microarray prediction (test pre-
diction) versus PCR validation, which was defined as the
gold standard for this purpose. For all cases, microarray
data were generally predictive of follow-up PCR status.
Results show that (1) caCORRECT was able to moder-
ately improve biomarker selection power for typical
microarray data (area under the curve increase from
0.777 to 0.786); and (2) caCORRECT was able to
improve biomarker selection power for microarrays
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increase from 0.723 to 0.751). Importantly, caCORRECT
had no undesired effects on the predictive power of
clean data. Thus, caCORRECT should be suitable for
datasets of unknown quality; in this setting, reliability
would be expected to improve if the arrays contain sig-
nificant artifact, while it would be unlikely to degrade if
array artifacts are insignificant.
Affycomp
Cope et al. have provided a benchmark [20] by which to
assess gene expression from two spike in datasets, one
on the HG-U133A and the other on the HG-U95A plat-
form [8]. Their spike in arrays were all prepared using
the same cRNA stock mixture, with the exception of 16
transcripts which were added in concentrations from 0
to 1024 picoMolar. These 16 transcripts were applied
(in triplicate) in a cyclic Latin square design. As a result,
the fold change between any two arrays for these 16
transcripts is known, while the fold change for all other
transcripts is expected to be 1 (no change). The affy-
comp package, available from http://bioconductor.org/,
provides many statistics and figures of merit with which
to compare the accuracy of gene expression in the con-
text of detecting known fold change between pairs of
arrays. Affycomp provides a uniquely public way to
assess caCORRECT without the need to synthetically
worsen the data. Figure 10, panels A and B, show
caCORRECT’s performance on the HG-U95A data set
as a plot of false positive rate versus true positive rate
(ROC curve). RMA after caCORRECT was the best
overall performer, as measured by Area Under the
Figure 5 Effect of artifact magnitude and preprocessing procedure on error of gene expression estimation. The size of applied artifacts
was fixed at 75 probes in diameter. Error is calculated as the average absolute difference, in the log domain, between original gene expression
and expression measured after addition of artifacts. Error bars represent the standard deviation calculated across 3 trials.
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Page 7 of 16Curve (AUC) for less than 100 false positives (0.830 for
RMA after caCORRECT, 0.821 for RMA alone, and
0.818 for RMA after Harshlighting). AUC gains from
caCORRECT were most noticeable for the TAXY
method, which does not provide any additional outlier
detection like that inherent in RMA, MAS5.0 and PLIER
(0.760 for TAXY after caCORRECT, 0.740 for TAXY
alone, and 0.719 for TAXY after Harshlighting). Impor-
tantly, the poorest-quality chip (Figure 10, panel C) was
thrown out by the original authors as part of the cano-
nical affycomp benchmark– a decision which was
recently justified quantitatively [21]. Still, examples of
chips on which caCORRECT has detected obvious arti-
facts (Figure 10, panel D) remain in the HG-U95 spike
in data. For the HG-U133A spike in dataset, which had
less detected artifacts, improvements due to caCOR-
RECT were more modest
It is almost never a good idea to run caCORRECT on
batches with 3 or fewer chips, although it is hard to ima-
gine a reliable microarray experiment so small. Affycomp
data, however, followed a rarely achieved design in which
there are 3 technical replicates of each sample. Arteaga-
Salas et al. were able to apply their method for correcting
small batches of replicates by splitting up the affycomp
data set [17]. They have previously reported performance
as the fraction of spike in genes from affycomp HG-
U133A to have their RMA-calculated fold-change rank
improved or worsened as a result of correction. Processing
Figure 6 Effect of artifact size and preprocessing procedure on error of gene expression estimation. The size of the artifact describes the
diameter of the circular artifact, with negative sizes indicating magnitude-reducing artifacts. The magnitude of applied artifacts was fixed at 2
fold (increase) or 0.5 fold (decrease) probe intensity in the footprint of the artifact. Error is calculated as the average absolute difference, in the
log domain, between original gene expression and expression measured after application of artifacts. Error bars represent the standard deviation
calculated across 3 trials.
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Page 8 of 16batches of 3 technical replicates at a time, they report
45.70% improved ranks, while caCORRECT, processing
the entire dataset at once, improved ranks of 10.81% of
spiked in genes. However, they report 38.60% worsened
ranks, while caCORRECT worsened the ranks of only
9.52% spiked in genes. This result is consistent with
caCORRECT’s conservative design, but suggests that
Arteaga-Salas’s correction method may also be appropriate
for experimental designs with available technical replicates
for every sample.
Discussion
caCORRECT is designed to correct spatial artifacts from
batches of Affymetrix microarrays and to provide a
robust global normalization before gene expression is
calculated from the multiple probe values. Other sources
of microarray noise which lack a spatial basis, such as
RNA degradation, are not expected to be detected or
altered by caCORRECT. Because modern chip layouts
have more or less random arrangement of probes, these
outlier probes are unlikely to be arranged in clusters on
the chip surface large enough to be counted as artifacts.
This same property also protects natural biological up
regulation or down regulation of genes from being
marked as artifacts. caCORRECT’s performance is tied
to both the size and quality of the batch being consid-
ered. First, the resolving power of artifact identification
increases as the natural variance between samples
decreases. Thus, the more similar samples are in a
batch, the more powerful caCORRECT is. While techni-
cal or biological replicates are ideal, almost any cohort
of arrays from the same study is an acceptable input. It
Figure 7 Gene Expression of NNMT and PRKAB1 Biomarkers across Multiple Tissues and Platforms. The differences in gene expression
among three common subtypes of renal cell carcinoma are shown. In all panels, blue Xs and “CC” denotes clear cell, red Os and “CHR” denote
chromophobe, and magenta squares and “ONC” denote Oncocytoma. (Panel A) Gene expression output from microarray data using MAS5,
(Panel B) Gene expression from the first PCR experiment performed by the authors, (Panel C) Gene expression from follow-up PCR study #2
performed at a core facility, (Panel D) Comparison of expression ratios across tissues and platforms. Box and whiskers plots show the median, q1,
q3, max and min values for samples grouped by subtype.
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from two or more studies as long as they are from the
same platform. Combination of data from different labs
can easily introduce batch effects, however, and so this
is generally not recommended. Second, even though
s a m p l es i z ei sa c c o u n t e df o rw i t h i nc a C O R R E C T ’sv a r -
iance score, the resolving power of artifact detection is
diminished with smaller batches. For any size batch, but
especially for those with less than 6 chips, we suggest
watchful use of caCORRECT. Users should inspect the
images provided by caCORRECT to confirm the quality
of the data set. For chips with excessive artifact coverage
(>50%), we suggest removing them altogether to avoid
relying too much on imputation. We realize that this is
not an attractive option for many researchers with small
experiments, in which case we recommend including
more chips or using caCORRECT only for quality
assessment purposes.
While most existing gene expression algorithms
include measures to remove artifacts, they are sub-opti-
mal in that they ignore information about the spatial
configuration of artifact probes. Using a visible scratch
as an example, we have shown that caCORRECT’s heat
map-based outlier detection performs better than those
methods that are purely based on statistical analysis of
spatially-independent probe data. Blemishes such as the
ones shown in this case study are common in microar-
ray data and should be ignored or down-weighted when
calculating gene expression.
Quantile normalization has been widely adopted by
the microarray community as a way to remove global
chip bias. We have shown that quantile normalization,
while generally useful, can be counter-productive in
datasets that have a chip with significant artifacts. First,
good data from a chip with artifacts will be wrongfully
displaced during normalization, i.e. high intensity arti-
facts will lead to underestimation for probe sets not in
the footprint of the artifact. Second, probe data from
otherwise clean chips or clean regions on damaged
chips may be corrupted or distorted during quantile
normalization if artifact data appear anywhere in the
batch. caCORRECT alleviates this corruption by
employing an artifact-aware quantile normalization
scheme that is less susceptible to such data corruption
or warping.
As an extension of the pitfalls of both the normaliza-
tion and artifact identification schemes provided by
modern microarray processing software, we show that
caCORRECT combines advances in these two areas to
Figure 8 Examples of artifacts present for biomarker
identification analysis. Images are heat maps of residuals for two
pairs of arrays, with red color indicating higher-than-expected probe
intensity, and blue color indicating lower-than-expected probe
intensity. Heat maps such as these reveal the intensity and type of
artifacts after caCORRECT normalization and artifact identification,
but before removal. Panels A and B show naturally occurring
artifacts on two chips from the Schuetz et al. dataset. Blue color in
the upper right quadrant of panel A indicates data in this region is
artificially low. Multiple small compact artifacts, both red and blue,
can also be seen. Panel B shows more examples of naturally
occurring artifacts, including a large artifact on the right edge of the
chip. In panels C and D respectively, synthetic circle-shaped hot-
spot and black-hole type artifacts have been applied to the same
chips from panels A and B. The artifact in C appears red due to its
artificially high probe intensity values. In panel D, the synthetic
black-hole artifact is visible as a blue circle.
Figure 9 Microarray Fold Change as a Predictor of PCR Fold
Change in RCC Samples, and the Effect of Artifacts and
caCORRECT Preprocessing. Genes were thresholded by magnitude
of observed log fold change in RMA-derived microarray data, and
considered truly differentially expressed if they exhibited more than
a 2x or less than a 1/2x fold change between classes CC and CHR
in the PCR data. Only genes for which PCR data were available
appear in this analysis. caCORRECT preserves data quality for arrays
without serious artifact (area under the curve increase from 0.777 to
0.786) and improves quality for arrays that have serious artifacts
(area under the curve increase from 0.723 to 0.751, but not all the
way back to 0.777).
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When operating upstream of PLIER, MAS5.0, and RMA
algorithms, caCORRECT reduces the error in gene esti-
mation, especially for cases of expression-lowering arti-
facts in MAS5.0, and expression-raising artifacts in
RMA. The former effect is most likely influenced by
MAS5.0’s tendency to declare transcripts as not present,
while the latter trend is most likely due to RMA’s use of
quantile normalization.
In contrast to caCORRECT, Harshlighting was
observed to increase error in gene expression in most
cases. Although the artifact segmentation results of
Harshlighting are visually intuitive, the median based
data replacement scheme appears to be unhelpful when
used upstream of smart gene expression software. This
is probably due to the fact that the median is a poorer
estimate of the expected probe intensity than the repla-
cement from model-based methods used by caCOR-
RECT and probe summarization software. This is
consistent with Troyanskaya et al.’sf i n d i n g st h a ts i n g u -
lar value decomposition imputation outperforms mean
replacement in the context of replacing missing gene
expression values [22]. It appears that for most artifacts,
the median replacement may imply false confidence,
Figure 10 Figures of merit derived from affycomp. Panels A and B show figure of merit “5b” generated by affycomp for the HG-U95A spike
in experiment, i.e. ROC curves for the task of identifying spiked in probe sets with known fold change of 2. Panel A is limited to 100 false
positives, as suggested by Cope et al., while Panel B shows the same, but for all genes in the data set. Legend entries with caC denote that
caCORRECT has been run on the data, and HL denotes that Harshlighting has been run on the data. “taxy” refers to the caCORRECT model of
gene expression, while “rma”, “mas5” and “plier” are computed with their respective R implementations. Panel C shows residuals (as colored in
figure 8 and figure 2) for “chip 54” from the experiment, which has been hard-coded to be excluded from the analyses by the authors of
affycomp. Panel D shows residuals for “chip21.” caCORRECT improves performance for RMA, TAXY, and PLIER, but is unable to help the poorly-
performing MAS5.0 for these data.
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detected and corrected by the simple methods inherent
in RMA, PLIER, dChip, or MAS5.0.
Although we have shown that using caCORRECT
improves the accuracy of derived gene expression data
and the assessment of fold-change between pairs of
arrays, this improvement in gene expression data quality
has yielded only modest improvement in the reliability
of biomarkers identified from a cohort of RCC samples.
Specifically, we have shown using ROC area under the
curve analysis that caCORRECT can improve the relia-
bility of biomarkers identified from data affected by
severe chip artifacts, without degrading performance on
clean data. For the task of identifying differentially
expressed genes from a cohort, much redundancy exists
in the data themselves, and the impact of a single bad
quality chip on the overall experiment is understandably
small. The largest impact of caCORRECT is expected in
applications which are relatively data-poor, or where the
information on a single array is precious. The affycomp
benchmark is such a “data-poor” application where dif-
ferential expression is assessed based on head-to-head
comparisons. The evidence that caCORRECT improves
fold change assessment in the affycomp data thus sup-
ports the hypothesis that caCORRECT may be more
noticeable in data-poor situations. An application of this
is a clinical scenario in which a cohort of arrays is used
to train a predictive model, but a single microarray is
used to determine diagnosis or treatment decisions for a
single patient. While throwing out a poor quality array
may be suitable practice during model training, it is not
an option during testing. A method such as caCOR-
RECT could prove to be the difference between a cor-
rect and an incorrect clinical decision.
Conclusions
We have demonstrated two fundamental reasons why
caCORRECT represents a theoretical improvement over
previous methods, as well as empirical evidence showing
improved performance in gene expression accuracy and
subsequent biomarker selection in the presence of
severe artifacts and in the affycomp data. We expect
that caCORRECT will be helpful for new experimenta-
tion as well as for revisiting the conclusions of archived
microarray data that may suffer from artifacts.
Methods
For all “caCORRECT” in this manuscript, version 2.1 of
caCORRECT was used, as provided at http://cacorrect.
bme.gatech.edu. The canonical bioconductor R-imple-
mentations of Harshlighting, RMA, MAS5.0, PLIER, and
affycomp were also used. What follows in this section is
a brief review of the previously published caCORRECT
procedures which are pertinent to this study, as well as
a description of the improvements which have been
made since previous publication [12]. Much of the fol-
lowing text has been reproduced with modification from
RAM’s doctoral dissertation [23].
Variance scoring
The cornerstone of caCORRECT’s outlier detection is
the concept of variance scoring, which is a description
of each probe’s tendency to be an outlier. Calculation of
this score, h, is similar to conducting a t-test for
whether or not the observed probe intensity for a given
chip belongs to the observed distribution of probe inten-
sities for all other chips in the dataset. A key feature of
caCORRECT is that this distribution is estimated and
updated multiple times during the course of a single
caCORRECT session. Because of this dynamic updating,
it is possible to identify subtle artifacts or pardon false
artifacts that may have been misdiagnosed initially.
Please refer to File01_supplement.pdf, “Supplemental
Methods”, for a more detailed description of how the
variance score is calculated.
Artifact segmentation
O n c et h ev a r i a n c es t a t i s t i c ,h, has been calculated for
each probe on each chip, false-color heat maps of h,
showing probes in their original spatial layout, are gen-
erated to display regions of high noise. For a good qual-
ity microarray chip, h will represent biological variation
in RNA expression for the sample. In this case, h will be
distributed independently and nearly-uniform in magni-
tude throughout the chip. More commonly, however,
protocols do not achieve uniform hybridization due to
uneven drying, formation of salt streaks, scratching of
the microarray surface due to contact with skin or dust,
miscalculated hybridization times, or failure to control
environmental variables such as ozone [24]. All of these
most common mistakes result in localized regions of
large h (artifacts) on the heat map.
caCORRECT uses a simple sliding window method to
flag probes that meet two conditions: (1) they exist in
regions of other high h-scoring probes, and (2) they have
high h scores themselves. These two conditions ensure
that most of the obvious artifacts are caught, but that
most of the naturally occurring biological variance goes
unnoticed. Because the intended platform for caCOR-
RECT is a web-based grid service, artifact identification
has been streamlined for speed and memory efficiency.
More computationally intense methods such as active
contours, PDE-based methods, or shape matching have
been excluded in favor of a quick marching window algo-
rithm that seems to work well for a wide range of data.
To remove any global chip effects that arise from sample
preparation or amplification, normalization is performed
as described in the following section.
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Quantile normalization reduces noise in microarray
experiment replicates by forcing the intensity distribu-
tion of each chip to be identical [Bolstad B: Probe level
quantile normalization of high density oligonucleotide
array data, 2001]. The critical assumption behind quan-
tile normalization is that for large genome-wide studies
such as microarrays, the number of genes that are invar-
iant to the experimental variables far outnumbers the
number of biomarkers– genes that respond to or predict
experimental variables. Quantile normalization is gener-
ally good for the microarray problem, where the distri-
butions are poorly defined and parametric methods such
as median centering or Z-score normalization have their
underlying assumptions violated. The power of quantile
normalization comes with a major caveat. If the probe
intensities of the chips are not distributed similarly, the
algorithm will indiscriminately warp all the distributions
to be the same, including any that may have been cor-
rect initially. Fortunately, it is a reasonable assumption
that high-quality microarray data from a single source
on a single platform follow the same distribution.
Unfortunately, this high quality assumption is not valid
for much real-world data, where chip artifacts can sig-
nificantly alter the distribution of intensities on a chip.
One bad chip can warp the others when quantile nor-
malization is performed, thus compromising the repro-
ducibility of the entire data set. A way to alleviate this
problem is to identify artifacts before quantile normali-
zation, and set them aside temporarily. In theory, perfect
knowledge of artifacts would allow for perfect correc-
tion. This process is called “artifact-aware quantile nor-
malization.” caCORRECT uses four iterations of artifact-
aware normalization and artifact identification in order
to achieve a near steady-state normalization result with
a relatively small amount of computation time.
To illustrate the invasive effect that artifacts can have
on a dataset when quantile normalization is performed,
synthetic microarray data were generated in the follow-
ing manner: Six high-quality chips from the Schuetz et
al. dataset [25] were chosen, one of which was set aside
to receive artifacts. One third of the selected chip was
modified by a multiplicative factor of 0.5, representing a
low-intensity artifact. A different third of the selected
chip was modified by a multiplicative factor of 10, repre-
senting a high-intensity artifact. These six chips were
then processed using caCORRECT, and the probe inten-
sities were monitored for warping at each intermediate
step.
Artifact replacement and probe intensity model
Once artifacts have been identified, a clean dataset is
generated with the artifactual data appropriately
replaced. The current version of caCORRECT uses a
data imputation that is mathematically similar to the
model used by RMA and others [5,9,10]. Notably, so-
called perfect-match and mismatch probes are treated
identically, i.e. we do not use PM-MM. In this scheme,
the artifact-flagged probe level data is replaced with the
best-fit estimate for that probe, given the model and
data from non-artifactual probes on all of the chips
being processed.
Observed microarray intensity values after global nor-
malization are modeled as a multiplicative combination
of target RNA abundance (gene expression) and probe-
specific effect (probe affinity). The model is given as:
xb,p,j = θp,jab,p + εb,p,j,
where xb,p,j is the observed intensity for the b
th probe
in the p
th probe set on the j
th chip, θp,j is the gene
expression term, ab,p is the probe affinity term, and εb,p,j
is the additive error term.
The set of equations for the p
th probe set using an
additive model of error can be represented in the fol-
lowing matrix form, given a set of N chips and Bp
probes in the p
th probe set.
Xp = θpap + εp,
where
Xp =
⎡
⎢
⎣
x1,p,1 ··· xBp,p,1
. . .
...
. . .
x1,p,N ··· xBp,p,N
⎤
⎥
⎦,
θp =
⎡
⎢
⎣
θp,1
. . .
θp,N
⎤
⎥
⎦,
ap =
 
a1,p ··· aBp,p
 
,
and
εp =
⎡
⎢
⎣
ε1,p,1 ··· εBp,p,1
. . .
...
. . .
ε1,p,N ··· εBp,p,N
⎤
⎥
⎦.
We define the solution to this matrix equation as that
which minimizes the Frobenius norm of the above error
matrix εp as defined below.
   εp
   
F =
     
 
 
N  
j=1
Bp  
b=1
 
εb,p,j
 2
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be derived from the singular value decomposition (SVD)
of Xp. Here, the SVD of Xp is given in the form of Xp =
USV
T, such that,U ∈  N×N, S ∈  N×Bp and V ∈  Bp×Bp.
If the largest singular value in S, s1, is arranged as the
first diagonal element of S,t h e nθp is s1 times the first
column of U and aT
p is the first column of V.
We chose to introduce the additional constraint that
the geometric mean of the lumped probe affinity terms
ab,p equals one. The number one is arbitrary here, but it
allows the convenient interpretation that the values of
gene expression, θ p,j, are on the same scale as the
probe intensities, xb,p,j.T os a t i s f yt h i sc o n s t r a i n t ,t h e
earlier solution for ap and θp c a ns i m p l yb es c a l e db y
respective multiplication and division.
Imputation of artifact values
With values of θp and ap l e a r n e df r o mS V D ,t h ep r o b e
intensities which are expected from the model can be
generated via the multiplication θpap Incorporation of
artifacts into this model is done in the following 2-step
Expectation-Maximization algorithm until θp and ap
converge.
1) Estimate model parameters θp and ap from the SVD
of the observed data Xp.
2) Replace known artifact values in Xp with informa-
tion from the corresponding elements of θp ap.
This procedure of replacing values in Xp with values
from θp ap has the effect of reducing corresponding
values of εp to zero, and thus has the property of never
increasing the Frobenius norm of εp. Since step 1 is a
global minimization of the Frobenius norm of εp given
Xp, and step 2 alters Xp in a way that can only further
decrease this error, the entire procedure is guaranteed
to converge due to the non-increasing nature of the
error function, which is naturally bounded by zero.
Troyanskaya et al. have previously used a similar
“SVDImpute” procedure for missing gene expression
data [22]. Please see additional file 1, “Supplemental
Methods”, for further details.
Datasets and synthetic artifact generation
In order to quantify the ability of caCORRECT to
improve data quality, we altered public microarray
datasets with a variety of randomized synthetic arti-
facts, and then processed the altered data with caCOR-
RECT or Harshlighting. Datasets were generated from
a variety of clinical cancer studies using different
microarray platforms. To date, the caCORRECT web-
site has been tested with data from 18 different Affy-
metrix platforms, but the results of our synthetic
artifact analysis which are presented here are limited
to our in-depth study of two key data sets. Three
separate experiments were performed involving appli-
cation of synthetic artifacts.
Third party artifacts on Hess et al. data
First, we obtained a large data set that was originally
generated by Hess et al. [26] in the study of breast can-
cer, and then later used as part of MAQC phase-II
study on classifier performance. This original data set
consisted of 130 high-quality samples assayed on the
Affymetrix HG-U133A platform. The Hess et al. study
divided samples into training (n = 81) and validation (n
=4 9 )s e t sa n dw er e t a i nt h i sd istinction. Chips in the
validation set were selected for synthetic artifact manip-
ulation by an independent team lead by Wendell Jones
of Expression Analysis, (previously unaffiliated with
caCORRECT). Two types of artifacts were investigated
here: (1) a “black hole” artifact in which an elliptical
region of the microarray had probe intensities lowered
severely, and (2) a “hot spot” artifact in which an ellipti-
cal region of the microarray had probe intensities raised
severely. Twenty digitally altered copies of each of the
original 49 chips were prepared as follows: A single arti-
fact with random orientation and location was applied
to each chip (ten chips received “black holes”,a n dt e n
received “hot spots”). For each of the altered chips, gene
expressions were calculated both before and after
caCORRECT’s complete artifact detection and value
imputation. Expression data for all probes were deter-
mined both using MAS5 in Expression Console and the
R implementation of RMA. Each of the estimated gene
expressions from the altered chips was then compared
to the “true” gene expression values obtained from the
respective original, unaltered chip to yield an error value
representing the deleterious effect of the artifact on
gene expression estimation. The errors for each probe
set (22283), each chip (49), and each artifact replicate of
a given type (10) were then pooled together to form dis-
tributions of errors of size n = 10,918,670. Eight such
distributions were created in total, representing the
combinations of two gene expression methods, two arti-
fact types and either unprocessed data, or for data
cleaned with caCORRECT.
Artifacts generated on data from Hess et al
A common criticism of our synthetic artifact work is
that the size and severity of tested artifacts (for example
t h o s ep r o v i d e db yJ o n e s ’ team) are rarely observed in
practice. While we have encountered many chips pla-
gued by large, severe artifacts, (see http://arraywiki.bme.
gatech.edu/index.php/Hall_of_Fame for some examples
[27]), we set out here to investigate how the magnitude
and size of artifacts may affect our previous conclusions
as to the usefulness of caCORRECT. Thus, we have cre-
ated a second set of synthetic artifact data specifically
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Page 14 of 16for this purpose by our own application of artifacts to
the same breast cancer dataset from Hess et al that
Jones’ team used. Only the 15 highest quality arrays (via
visual inspection of heat map images) from this dataset
were used in order to both speed up computation as
well as to more precisely isolate the effects of our syn-
thetic artifacts. For a variety of sizes and magnitudes,
circular regions of the array were altered multiplica-
tively. Care was taken so that no more than 1/2 of the
radius of the circular insult appeared off of the chip.
The final gene expression obtained from the altered
array was then compared to the gene expression
obtained from the original unaltered array, and the aver-
age of the relative error for each probe set on the array
was stored. For each pair of size and magnitude, this
process was repeated a total of 3 times.
Artifacts observed and generated on data from Schuetz
et al
Finally, a realistic mixture of less-severe artifacts were
applied to the Schuetz et al. [25] dataset in order to
monitor the effect of typical artifacts on differential gene
finding, and the ability of caCORRECT to ameliorate
these effects. This data set consisted of 20 Renal Cell
Carcinoma (RCC) samples assayed on the Affymetrix
HG-Focus Platform by Schuetz et al. Samples were clas-
sified by tumor subtype: Clear Cell (CC), Oncocytoma
(ONC), and Chromophobe (CHR). For biomarker selec-
tion purposes, samples were combined into two classes:
seven CHR or ONC versus thirteen CC.
Artifacts observed on data from West et al
The dataset which was used to showcase real-world arti-
fact removal and replacement was a set of 49 Hu-6800
Affymetrix microarrays from the study by West et al.
This study investigated Estrogen Receptor and lymph
node metastatic status [28]. This data set is chosen
because it used an older version of Affymetrix chip in
which the properties of artifacts are more easily visua-
lized than on modern chips.
PCR Validation
To determine the effect that caCORRECT had on the
ability to correctly identify biomarkers of disease from
microarray data, a panel of 96 genes of interest for RCC
was assembled for PCR study in two phases. These
genes were identified from a combination of genes pre-
viously identified in the literature as well as a set of
genes whose biomarker status was disagreed upon
between the caCORRECT and non-caCORRECT ver-
sions of the Schuetz et al. data sets using omniBiomar-
ker (http://omniBiomarker.bme.gatech.edu). All PCR
analysis was performed on independent patient tissue
samples with respect to those used for the microarray
analysis.
Gene expression was assessed by quantitative RT-PCR,
using total RNA from fixed tissues of 17 clear cell and 7
chromophobe RCC patients. Duplicate experiments
were performed according to published protocols with
minor modifications: Histological sections were deparaf-
finized with ethanol and xylene, and cells of interest
were microdissected with a sterile scalpel. Tissues were
digested in buffer containing proteinase K at 60°C over-
night. RNA was extracted with phenol/chloroform, and
genomic DNA was removed with DNase. RNA quality
and quantity were assessed with a Bioanalyzer (Agilent
Technologies). Up to 3 μgo fR N Aw a su s e df o rf i r s t
strand cDNA synthesis with Superscript III (Invitrogen).
PCR was performed with a custom-designed Taqman
Low Density Array (LDA, Applied Biosystems) in a 96-
well microfluidic card format, using the ABI PRISM
7900HT Sequence Detection System (high-throughput
real-time PCR system). Gene expression data were nor-
malized relative to the geometric mean of two house-
keeping genes (18S, ACTB). LDA runs were analyzed by
using Relative Quantification (RQ) Manager (Applied
Biosystems) software.
Relative normalized PCR gene expression was com-
pared in renal tumor subtypes. Genes were declared as
being “validated by PCR” if they had an average fold
change between classes of magnitude greater than 2,
corresponding to an average Ct (threshold cycle) value
difference of 1.
Additional material
Additional file 1: Supplemental Materials. Additional descriptions of
methodology for: calculation of variance score, implementation of gene
expression model imputation, biomarker selection, and PCR
experimentation
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